# An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipolar I Disorder (ALKS 3831-315)

> **NCT07744113** · — · AVAILABLE · sponsor: **Alkermes, Inc.**

## Conditions studied

- Bipolar 1 Disorder
- Schizophrenia Disorder

## Interventions

- **DRUG:** OLZ/SAM

## Key facts

- **NCT ID:** NCT07744113
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07744113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07744113, "An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipolar I Disorder (ALKS 3831-315)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07744113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*